Bibliography
- Specifically claimed in claim 8 of GB-1397436, patent of ad- dition to GB–1338169.
- Specifically claimed in claim 15 of GB–1565966.
- KUBO et al.: Problem pharmaceutical patents. World Patent Information (1996) 18(4):227–233.
- For a discussion of recent litigation in relation to second use claims in Europe see COOK T: Pharmaceutical patent liti-gation in Europe. Exp. Opin. Ther. Patents (1999) 9(2):181–187.
- DUEHOLM K: A strategic analysis of patents covering receptors and their use as research tools filed since 1993 by three major companies. Exp. Opin. Ther. Patents (1998) 8(7):871–888.
- See e.g., W09516918, W09527072, W09622529, W09701560, applications in the names respectively of Com-biChem, Inc.; Pharmagenics, Inc.; Arqule, Inc.; and Pharma-copoeia, Inc. See also W09635953 to Arqule, Inc., which seeks product claims, both in relation to the a library, and also to a broad spread of NCEs of potential utility in HIV treatment discovered by means of such techniques.
- May & Baker vs. Boots (1950) RPC 6723.
- Olin Mathieson vs. Biorex (1970) RPC 157 193.
- Article 83 of the EPC.
- Article 84 of the EPC.
- Article 138(0(b) of the EPC.
- Biogen vs. Medeva (1997) RPC 1.
- Decision T 292/85 OJEPO (1989) 275.
- Decision T 694/92 OJEPO (1997) 408.